The FDA has approved Novartis' Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing a calcium channel blocker, an angiotensin receptor blocker, and a diuretic, for the treatment of hypertension. Patients may be switched to Exforge HCT if their blood pressure is not adequately controlled on dual combinations of its components. Exforge HCT is not indicated for the initial therapy of hypertension. This approval was based on data from a clinical study in more than 2000 patients with moderate to severe hypertension. Patients treated with Exforge HCT demonstrated significantly greater reductions in systolic and diastolic blood pressures compared to all dual combinations of its components at the same doses.